Other Event

Other Event

Other Adverse Events are non-serious adverse events that exceed a specific frequency threshold (typically 5% within any study arm). These events are reported to provide comprehensive safety information about all noteworthy adverse occurrences during clinical trials. Each other event is categorized by term, organ system, assessment type, and source vocabulary for standardized reporting.

Other Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Other Event

Study -> Results Section -> Adverse Events Module -> Other Event -> Other Event Stats

Other Event


Ignite Creation Date: 2025-12-25 @ 1:25 AM
Ignite Modification Date: 2025-12-25 @ 11:36 PM
NCT ID: NCT01903993
Term: Aspartate Aminotransferase Increased
Organ System: Investigations
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDRA (21.1)
Notes: None
Study: NCT01903993
Study Brief: A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
Other Event Stats (If Any):

Other Event Stats

Group ID # Events # Affected # At Risk View
EG000 1 1 135 View
EG001 21 10 142 View